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Abstract Medulloblastoma is the most common malig-
nant brain tumor in childhood. Molecular studies from
several groups around the world demonstrated that
medulloblastoma is not one disease but comprises a col-
lection of distinct molecular subgroups. However, all these
studies reported on different numbers of subgroups. The
current consensus is that there are only four core sub-
groups, which should be termed WNT, SHH, Group 3 and
Group 4. Based on this, we performed a meta-analysis of
all molecular and clinical data of 550 medulloblastomas
brought together from seven independent studies. All cases
were analyzed by gene expression proﬁling and for most
cases SNP or array-CGH data were available. Data are
presented for all medulloblastomas together and for each
subgroup separately. For validation purposes, we compared
the results of this meta-analysis with another large
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DOI 10.1007/s00401-012-0958-8medulloblastoma cohort (n = 402) for which subgroup
information was obtained by immunohistochemistry.
Results from both cohorts are highly similar and show how
distinct the molecular subtypes are with respect to their
transcriptome, DNA copy-number aberrations, demo-
graphics, and survival. Results from these analyses will
form the basis for prospective multi-center studies and will
have an impact on how the different subgroups of medul-
loblastoma will be treated in the future.
Keywords Medulloblastoma  Pediatric brain tumor 
Subgroups  Meta-analysis
Introduction
The embryonal brain tumor medulloblastoma is the most
common malignant brain tumor in childhood. However, in
several studies using transcriptional proﬁling we and others
have shown that medulloblastoma is not a single disease, but
in fact comprises a collection of clinically and molecularly
diverse tumor subgroups [1, 9, 15, 19, 20, 25]. Two of these
subgroups, characterized by either activated WNT or SHH
signaling, consistently showed the most distinct genetic
proﬁles. Recently, it was found that they also have different
cellular origins [7]. Non-WNT/non-SHH tumors are more
closely related to each other and the previously mentioned
proﬁling studies reported on different numbers of subgroups
within this group of medulloblastomas. Initially, three more
subgroups were identiﬁed [9], characterized by elevated
expression of neuronal differentiation genes (subgroups C
and D), or the expression of photoreceptor genes (subgroups
D and E). Another more recent study even identiﬁed four
subgroups within the Non-WNT/Non-SHH group with sub-
groups c2 and c4 corresponding to the previously identiﬁed
subgroups C and D [9], respectively [1]. For subgroup E
according to Kool et al. [9], two subsets were identiﬁed (c1
and c5),which differedingeneexpressionpatterns causedby
the high frequency of MYC ampliﬁcations in c1 tumors.
However, the current consensus in the medulloblastoma ﬁeld
is that there are only four core molecular subgroups in
medulloblastoma, as recently agreed upon at a consensus
meeting in Boston (see also the manuscript by Taylor et al.
[24] in this issue). These four subgroups, which we will now
call WNT, SHH, Group 3 and Group 4, are the same four
subgroups as proposed in the study by Northcott et al. [15]
and Remke et al. [19, 20]. It is important to note, however,
thataslargercohortswillbeanalysedinthefuture,additional
subtypes with speciﬁc genetic aberrations or other molecular
or clinical properties might still be identiﬁed within each of
these core subgroups, as was recently demonstrated for SHH
medulloblastomas [14]. Having reached the consensus about
the four major subgroups we have now re-analysed all
the existing expression proﬁles from seven different studies
([1, 5, 9, 15, 19, 25]; McCabe et al., unpublished) and per-
formedameta-analysisofallavailablemolecularandclinical
data. Data for all medulloblastomas together and for each of
the four subgroups separately are presented in this paper and
compared with the data from another large cohort of
medulloblastomas in which subgroup afﬁliation was deter-
mined by immunohistochemistry.
Patients and methods
Patients
Original data from seven studies with a total of 550
medulloblastoma patients were used for this study (Table
S1). Information on gender, age at diagnosis, and histology
was available for 523 patients (95%). Pathology was
reviewed according to the 2007 WHO classiﬁcation for
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123central nervous system tumors [13]. One of these histo-
logical subtypes is characterized by extensive nodularity
(MBEN). Although we acknowledge that these cases are
different with respect to genetics, clinics and histology,
there was only a single case in all seven studies classiﬁed
as MBEN [15], which we have pooled with desmoplastic
medulloblastoma in our study. We categorized the patients
in three age groups: infants (aged\4 years), children (aged
4–16 years), and adults (aged[16 years). Information for
metastatic stage (CM1) at diagnosis was available for 432
patients (79%). Survival data were available for 388
patients (71%). The median follow-up time of survivors
was 5.4 years (range 0.1–20.3 years). Data on whether
patients received chemotherapy and/or radiotherapy were
available for 234 patients (43%). For validation, we used
the data from a largely independent medulloblastoma tissue
micro array (TMA) cohort with tumors from 402 patients.
Thirty-eight cases were also included in the Remke
expression proﬁling series [19, 20]. All these patient
samples were serially collected at the NN Burdenko Neu-
rosurgical Institute (Moscow, Russia) between 1995 and
2007. Subgroup information for all tumors on the TMA
was obtained by immunohistochemistry using antibodies
for the subgroup-speciﬁc protein markers b-catenin
(WNT), DKK1 (WNT), SFRP1 (SHH), NPR3 (Group 3),
and KCNA1 (Group 4) as reported in [15, 19]. Information
on gender, age at diagnosis, histology, metastatic stage at
diagnosis and survival was available for all 402 patients
(Table S1). As for the transcription proﬁling cohort
pathology was reviewed according to the 2007 WHO cri-
teria [13]. The median follow-up time of survivors in the
TMA cohort was 3.6 years (range 0.3–17.0 years).
Analyses
Medulloblastoma expression proﬁles generated on
Affymetrix 133A [1, 25], Affymetrix 133plus 2.0 [5, 9];
McCabe et al., unpublished), Affymetrix exon 1.0 arrays
[15], or Agilent arrays [19, 20], were available for all 550
patients. Data are accessible through the open access
database R2 for visualization and analysis of microarray
data (http://r2.amc.nl). Subgroup annotation for each
dataset was obtained from semi non-negative matrix
factorization (NMF) [6] using the 500 most differentially
expressed genes. Array-CGH or SNP data were available
for 383 medulloblastomas from ﬁve of the seven studies
[1, 5, 9, 15, 19]. Overall survival was calculated from the
date of diagnosis until death or last follow-up date.
Univariate survival analysis was performed using the
Kaplan–Meier method and log-rank test (SPSS 15.0). A
multivariate Cox proportional hazards regression model,
with overall survival as the dependent variable, was used
to test the independency of each prognostic factor that
was signiﬁcant by univariate analysis. Two-sided p\0.05
using 95% conﬁdence interval was considered statistically
signiﬁcant.
Results
Patient characteristics in the gene expression proﬁling
studies
The seven datasets used in this study were comparable
regarding most patient characteristics (Table S1). Only the
Thompson and Fattet series mainly included infants and
children, whereas all other series also included adult
medulloblastoma patients. The Remke series was even
enriched for adults accounting for almost 50% in this
cohort. In the McCabe series, only classic medulloblasto-
mas were included. Of all patients, 21% were infants (age
\4), 67% children (age 4–16) and 12% adults (age[16).
In the Thompson series, an equal number of males and
females were included, but all other series contained more
males than females. One of the aims of the meta-analyses is
also to overcome these cohort-speciﬁc biases. The median
age of all patients was 7.3 years (range 0.3–52 years)
(Table S1).
Four molecular subtypes in medulloblastoma
Group 4 tumors formed the largest group (34%) in this
meta-analysis, followed by SHH (28%) and Group 3
tumors (27%). WNT tumors represented the smallest
group (11%) (Fig. 1a). Distribution of these molecular
subtypes was, however, signiﬁcantly different between
the three age groups (p\0.001). Both among infants and
adults, SHH tumors were most prominent and represented
more than half of the cases, but in children they were
much less frequent (14%) (Fig. 1b–d). WNT tumors were
almost absent in infants (1%) and the frequency of Group
4 tumors was also much lower in this age group (11%). In
contrast, Group 3 tumors were hardly found in adults
(6%).
Gender distribution
Overall, medulloblastoma affects males (M) about 1.5
times more often than females (F) [13], which was also
evident from these combined series (Table S1). However,
the M:F ratios were signiﬁcantly different between the
molecular subgroups (p = 0.008) (Fig. 1e–h). WNT and
SHH tumors occurred almost equally in males and females,
whereas Group 3 and Group 4 tumors clearly affected
males about twice as often as females. This was found in
all three age categories.
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Fig. 1 Demographic distribution of medulloblastoma subgroups.
Subgroup distribution is shown for all medulloblastoma patients (a),
infants (age \4 years) (b), children (age 4–16) (c), and adults (age
[16) (d). Numbers on the Y axis indicate number of patients.
Male:female frequencies are shown for all four subgroups in all
patients (e), infants (f), children (g), and adults (h). Males are
indicated in blue, females in pink. Distribution of histological subtype
is shown for all four subgroups in all patients (i), infants (j), children
(k), and adults (l). Classic histology is indicated in dark red,
desmoplastic/extensive nodular histology in gray, and large cell/
anaplastic histology in orange. Frequencies of metastasized (green)
and non-metastasized (light green) cases are shown for all four
subgroups in all patients (m), infants (n), children (o), and adults (p).
Age distribution shown for males (solid lines) and females (dotted
lines) is plotted for each of the four subgroups: WNT (q), SHH (r),
Group 3 (s), and Group 4 (t). Numbers on the Y axis indicate the
frequency of that particular subgroup within the indicated age group
(in years) on the X axis among all patients
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123Histology distribution
Most medulloblastomas were of classic histology (70%),
followed by desmoplastic (16%) and large cell/anaplastic
(LCA) histology (10%), but their frequencies varied
between the different age categories (Fig. 1i–l). For
instance, in infants the frequency of desmoplastic tumors
was much higher (42%), but in children it was lower (9%).
In adults, a very low frequency of LCA tumors was found
(3%). Furthermore, there was a highly signiﬁcant differ-
ence between the molecular subgroups and their
occurrence within each histological variant (p\0.001).
Moreover, for each subgroup separately, the histological
frequencies were also different between the three age cat-
egories. For instance, there is a strong association between
desmoplastic histology and SHH tumors. In infants 39/44
(89%) and in adults all (n = 10) desmoplastic cases were
classiﬁed as belonging to the SHH subgroup. In children,
however, only 8/32 (25%) of the desmoplastic cases were
classiﬁed as a SHH tumor. Nearly all (97%) WNT tumors
had classic histology. Only 2/58 had LCA histology. Other
LCA tumors were almost equally distributed over the other
three molecular subgroups, but in infants they were almost
all (10/13) classiﬁed as Group 3 tumors.
Metastasis
Metastatic disease (M1–M4) at diagnosis was found in 103
of the 432 (24%) patients for whom the metastatic stage
was known (Table S1). As expected according to previous
reports [11, 20], in adults this percentage was much lower
(2%), while there was not much difference between infants
and children when the overall frequency of metastasis was
considered between these age groups (30 and 26%,
respectively). Among all patients, the highest frequency of
metastatic disease at diagnosis was found for Group 3
(30%) and Group 4 tumors (31%) and these percentages
were even higher in the infant group (47 and 36%,
respectively) (Fig. 1m–p). For SHH tumors, metastatic
disease was primarily found in infants (17%) and children
(22%), but not in adults. For WNT tumors, metastasis was
detected in 9% of cases and only in children.
Age distribution
Almost half (44%) of all medulloblastomas were diagnosed
in children between the age of 4 and 9 years, while 23%
occurred in older children (10–16), 21% in infants (0–3),
and 12% in adults ([16) (Table S1). The age distribution
for each of the molecular subgroups differed dramatically
(Fig. 1q–t). For instance, SHH tumors were most frequent
in infants and adults and also Group 3 tumors were com-
monly found in infants, but not Group 4 or WNT tumors.
These subgroups had their peak incidence later in child-
hood, at 5–13 or 10–12 years of age, respectively. No
differences in age distribution were found between males
and females.
Cytogenetics
Analysis of the a-CGH and SNP proﬁling data, available
for most cases in ﬁve of the seven medulloblastoma series,
showed clear differences in chromosomal aberrations as
has been reported for each of these series separately [1, 5,
9, 15, 19]. Complete or partial loss of chromosome 6 was
found in 35/41 (85%) of WNT-driven tumors, but was
nearly absent in all other subgroups (Fig. 2). Loss of 9q
was most frequently detected in SHH tumors (47%), but
was also found in Group 3 tumors (21%). Loss of 17p with
or without concomitant 17q gain was most frequently
found in Group 3 (loss 17p: 42%, gain 17q: 62%) and
Group 4 (loss 17p: 63%, gain 17q: 73%). Loss of 17p only
was also present in the SHH group (25%). Other chromo-
somal aberrations enriched in speciﬁc subgroups included
1q gain (Group 3, 35%), 3q gain (SHH, 27%), 7 gain
(Group 3 and 4, 55 and 47%, respectively), 8(p) loss
(Group 3 and 4, 33 and 41%, respectively), 8q gain (Group
3, 22%), 10q loss (most frequent in Group 3 (49%) but also
present in SHH (26%) and Group 4 (15%)), 12(q) gain in
Group 3 (17%) and Group 4 (20%), 16q loss (most frequent
in Group 3, 50%), and 18 gain in Group 3 (26%) and Group
4 (16%).
Survival analyses
Survival analyses for the combined series for which sur-
vival data were available showed a clear and signiﬁcant
difference in overall survival (OS) between the four
molecular subgroups. This was not only the case for all
patients together but also when infants or children were
analysed separately. Only for the adult category the dif-
ferences did not reach signiﬁcance (Fig. 3a–d). Both in
children and in adults, WNT tumors had by far the best
outcome with a 5- and 10-year OS of 95% in children
(n = 39) and a 5-year OS of 100% in adults (n = 5). The
worst outcome in all age categories was seen for patients
with Group 3 tumors (Infants 5- and 10-year OS 45 and
39%, respectively; children 5- and 10-year OS 58 and 50%,
respectively). In adults, 2/3 patients having a Group 3
medulloblastoma died. While the outcome for patients with
both Group 3 and 4 tumors was more or less similar in all
age categories, SHH tumors clearly had a better outcome
in infants (5- and 10-year OS 77%) compared to children
(5- and 10-year OS 68 and 51%, respectively) and adults
(5- and 10-year OS 75 and 34%, respectively). This is
likely associated with the high frequency of desmoplastic
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123histology among SHH tumors in infants, as it has been
demonstrated that desmoplastic/extensive nodular histol-
ogy in this age group is a marker of favorable prognosis
[21]. Histological subtyping indeed showed that especially
desmoplastic histology in infants predicts a very good
outcome (5- and 10-year OS 84%). In contrast, large cell
anaplastic (LCA) histology predicts a very poor outcome in
all age categories (infants 5-year OS 22%; children 10-year
OS 32%; in adults both patients with LCA histology died)
(Fig. 3i–l). Histological subtyping is also important within
molecular subgroups, especially for SHH tumors where the
histological subtypes show a large difference in outcome
(Fig. 3q–t). Infants and children with metastatic dissemi-
nation at diagnosis in general have a worse outcome than
patients without, but only in children this difference was
signiﬁcant (Fig. 3e–h). Also within SHH, Group 3 or
Group 4 tumors we see that patients with metastatic dis-
semination do worse than those without, but only for Group
4 patients this difference in overall survival was signiﬁcant
(Fig. 3n–p). Interestingly, all four patients with a WNT
tumor and metastatic disease survived (Fig. 3m).
MYC family oncogene ampliﬁcations
High-level gene ampliﬁcations are overall rarely observed
in medulloblastoma, but when they do occur, they most
frequently affect the MYC or MYCN oncogenes and only in
a very few cases the related MYCL gene. Almost all MYC
ampliﬁcations were identiﬁed in Group 3 tumors (24/27).
The other three cases were found in SHH (n = 1) or Group
4 tumors (n = 2). In contrast, MYCN ampliﬁcations mostly
occurred in either SHH (n = 10) or Group 4 tumors
(n = 12) and only rarely in Group 3 tumors (n = 3). All
three MYCL ampliﬁcations occurred in SHH tumors.
Patients having either a MYC or MYCN ampliﬁcation in
their tumor clearly have a signiﬁcantly worse outcome
compared to cases without ampliﬁcation (Fig. 4a). This is
true for all patients and also in a subgroup-speciﬁc manner,
Fig. 2 Overview of
chromosomal aberrations in the
four medulloblastoma
subgroups. Array-CGH and
SNP data were scored for loss
(green), gain (red), or no change
(gray) for all chromosomal
arms. Results were plotted as
frequencies at which these
aberrations occurred within
each molecular subgroup.
P values on the right indicate
whether there was a signiﬁcant
difference in the distribution of
these frequencies across the four
subgroups (Chi-square test). NS
not signiﬁcant
478 Acta Neuropathol (2012) 123:473–484
123All patients Infants Children Adults
WNT SHH GROUP 3 GROUP 4
WNT WNT WNT
SHH
SHH
SHH
SHH
GROUP 3
GROUP 3
GROUP 3
GROUP 3
GROUP 4
GROUP 4
GROUP 4
GROUP 4
M0 M0
M0
M0
M+ M+ M+
M+
DESMOPLASTIC
DESMOPLASTIC
DESMOPLASTIC DESMOPLASTIC
CLASSIC
CLASSIC
CLASSIC
CLASSIC
LCA LCA
LCA
LCA
DESMOPLASTIC
DESMOPLASTIC
DESMOPLASTIC
CLASSIC
CLASSIC
CLASSIC
CLASSIC
LCA
LCA
LCA
M0
M0
M0
M0
M+
M+
M+ M+
P < 0.001 P  = 0.015 P  = 0.003  NS
P = 0.001 NS P = 0.001  NS
P < 0.001 P  = 0.010 P  = 0.002 P  < 0.001
NS NS NS P = 0.024
P < 0.001 NS NS
ab cd
efg h
ij k l
mnop
qrst
Fig. 3 Overall survival (OS) analyses of molecular, clinical, and
histological subgroups within the gene expression proﬁling cohort
using Kaplan–Meier plots and log-rank tests. OS analysis of
molecular subgroups among all patients (a), infants (b), children
(c), and adults (d). OS analysis of metastasized (M1–M4, indicated as
M?) versus non-metastasized (M0) cases, plotted for all patients (e),
infants (f), children (g), and adults (h). OS analyses of classic,
desmoplastic and LCA histological subgroups among all patients (i),
infants (j), children (k), and adults (l). OS analysis of metastasized
(M1–M4, indicated as M?) versus non-metastasized (M0) cases,
plotted for each molecular subgroup: WNT (m), SHH (n), Group 3
(o), and Group 4 (p). OS analyses of classic, desmoplastic and LCA
histological subgroups plotted for each molecular subgroup: WNT
(q), SHH (r), Group 3 (s), and Group 4 (t). Numbers on the Y axis
indicate the fraction of surviving patients. Numbers on the X axis
indicate the follow-up time in months. NS not signiﬁcant
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Fig. 4 Overall survival (OS) analyses of cytogenetic subgroups using
Kaplan–Meier plots and log-rank tests for statistical signiﬁcance. Data
areshownforallpatientswithinthegeneexpressionproﬁlingcohort,for
theSHHsubgroup,forGroup3,andforGroup4.OSanalysisofpatients
having a MYC or MYCN ampliﬁcation versus patients not having these
ampliﬁcations. e–h OS analysis of patients harboring 10q loss versus
patients with a balanced 10q. i–l OS analysis of patients harboring 17p
loss versus patients with a balanced 17p. m–p OS analysis of patients
harboring17qgainversuspatients witha balanced17q.q–r OS analysis
of patients harboring 3q gain versus patients with a balanced 3q.
Frequencyof3qgainwithinGroup3andGroup4wastoolowtoperform
survivalanalyses.NumbersontheYaxisindicatethefractionofsurviving
patients.NumbersontheXaxisindicatethefollow-uptimeinmonths.NS
not signiﬁcant
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123except for Group 3 tumors. In this subgroup, patients
without MYC ampliﬁcation in their tumor do equally poor
as those carrying this alteration (Fig. 4a–d).
Survival analyses of cytogenetic groups
Other cytogenetic aberrations that were found to be sig-
niﬁcantly associated with outcome either in all patients or
within particular molecular subgroups included gain of 3q,
loss of 10q, loss of 17p, and gain of 17q (Fig. 4e–r). Gain
of 3q and loss of 10q was associated with poor outcome
only in SHH tumors. Chromosome 17 aberrations, most
frequently found in Group 3 and 4 tumors, were also
associated with a signiﬁcantly worse outcome within these
subgroups, and most clearly for Group 4 tumors. Loss of
17p, although much less frequent in SHH tumors, was also
associated with an unfavorable outcome in this subgroup
(Fig. 4j).
Multivariate analyses
Multivariate COX analyses were performed for the entire
cohort and for each subgroup separately using only the
factors that were signiﬁcant by univariate survival anal-
ysis (Table S2). For all patients, molecular subgrouping
was shown to be an independent prognostic factor with
relative risks of the various subgroups ranging from 1.9
to 4.1 compared to the WNT group (Table 1). MYC(N)
ampliﬁcations and loss of 17p also remained as inde-
pendent prognostic factors in the multivariate analysis
for all groups. For SHH tumors, both LCA histology and
gain of 3q were independent prognostic factors of
adverse outcome, while for Group 3 and 4 tumors, only
chromosome 17 aberrations (gain of 17q or loss of 17p,
respectively) remained signiﬁcant (Table 1). As different
treatment protocols may have inﬂuenced these survival
analyses, we also performed multivariate COX analyses
including only patients for we knew that they had
received radio- and chemotherapy. Furthermore, as data
on treatment were limited for some series, we also per-
formed the same analyses for non-infants only, assuming
that most of them received radio- and chemotherapy.
Results of these analyses, presented in Tables S2 and S3,
show that even after correcting for treatment or age
factors like histology, MYCN ampliﬁcation and gain of
3q remained signiﬁcant for all patients, and in the SHH
subgroup. Chromosome 17 aberrations remained signif-
icant after these corrections for the entire cohort, SHH
medulloblastomas and Group 4.
Data validation using an independent medulloblastoma
cohort
We used data from an independent large medulloblastoma
tissue microarray (TMA) cohort (n = 402) to compare the
results obtained from the GEP series. The TMA cohort
was analyzed by immunohistochemistry only and sub-
group annotation was obtained using speciﬁc-marker
antibodies as described in [15, 19]. Data presented in Fig.
S2 show that both the GEP and TMA cohorts were very
similar regarding distribution of molecular and histolog-
ical subgroups and the frequency of metastases at
diagnosis within each molecular subgroup and within the
different age categories. Only gender ratios for especially
W N Ta n dS H Ht u m o r sa p p e a r e dt ob es l i g h t l yd i f f e r e n t
for the TMA cohort, with more females in the WNT group
and more males in the SHH group. Finally, we also per-
formed overall survival analyses for this TMA cohort
similar to the analyses for the GEP cohort shown in
Fig. 4a–t. Data presented in Fig. S3 show that in general
these survival analyses look very similar to the ones from
the GEP cohort, but they revealed also some interesting
differences. For instance, patients with SHH medullo-
blastomas in the TMA cohort showed a much better
overall survival (5- and 10-year OS 87 and 77%, respec-
tively), which was mainly due to a better survival of
children (5- and 10-year OS 90 and 80%, respectively)
and adults (5- and 10-year OS 85 and 74%, respectively)
in this molecular subgroup. In contrast, patients with
Group 3 medulloblastomas did much worse. No patient
with a Group 3 tumor in this series survived longer than
124 months. Moreover, patients with WNT or Group 4
tumors, and especially those in adults, did worse than the
ones in the GEP cohort.
Table 1 Multivariate overall survival analyses
Prognostic factor RR CI low CI high P value
All patients (n = 204)
Subgroup 0.036
SHH vs. WNT 1.9 0.4 8.9 0.4
Group 3 vs. WNT 4.1 0.9 18.2 0.065
Group 4 vs. WNT 1.9 0.4 8.7 0.4
MYC(N) ampliﬁcation yes vs. no 3.4 1.7 6.5 \0.001
17p loss yes vs. no 2.4 1.4 4.3 0.002
SHH medulloblastomas (n = 54)
Histology 0.001
Desmoplastic vs. Classic 0.3 0.1 1.1 0.071
LCA vs. Classic 8.9 2.0 40.6 0.005
3q gain yes vs. no 4.5 1.5 13.9 0.008
Group 3 medulloblastomas (n = 44)
17q gain yes vs. no 2.6 1.0 6.6 0.049
Group 4 medulloblastomas (n = 79)
17p loss yes vs. no 3.6 1.2 10.8 0.020
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The meta-analysis presented here represents the largest
series of biology data on medulloblastoma reported so far.
The data clearly demonstrate that medulloblastoma is not a
single disease. The four major subgroups (WNT, SHH,
Group 3, and Group 4) differ in many aspects. They are
transcriptionally, genetically, demographically, clinically,
and prognostically distinct, conﬁrming earlier reports in
smaller series [1, 3, 9, 15, 19, 25]. Most likely, they will
also have different cellular origins, as has already been
shown for the WNT and SHH subgroups [7, 8, 23, 26]. The
cellular origin of Group 3 and 4 medulloblastomas is still
unknown. Several of the earlier proﬁling studies showed
that there might even be ﬁve or six subgroups of medul-
loblastoma [1, 9, 25], with further subdivisions of Group 3
and Group 4. An analysis performed on the combined GEP
cohorts under the assumption that there were ﬁve or six
subgroups showed that there are indeed subsets present
within these subgroups with transcriptional and genetic
differences, but demographically they were not different
(data not shown). Collectively, these data demonstrate that
there are only four core disease subgroups of medullo-
blastoma, with a yet unknown number of subsets within
each subgroup. Subsets also exist within the SHH subgroup
as we and others recently demonstrated [14, 18]. These
subsets show transcriptional and genetic differences and
seem to be associated with the different age groups (infants
vs. adults; [14]) that exist within the SHH subgroup and
with the presence of P53 mutations [18]. Potentially, they
could actually represent different disease variants with
different cellular origins, which might explain the bimodal
age distribution of SHH medulloblastomas. The meta-
analysis data also show that prognostic factors like meta-
static stage, histology, MYC and MYCN ampliﬁcations, 10q
loss, 17p loss, and 17q gain, previously reported for
medulloblastoma as a single disease [11, 12, 17], remain
prognostic in these combined series of all patients. How-
ever, our data now show for the ﬁrst time how they all
perform in the context of different subgroups. For instance,
the observation that medulloblastomas with chromosome
17 aberrations have an adverse outcome is due to the fact
that they are most frequent in Group 3 and Group 4
medulloblastomas, which fare worse than the WNT and
SHH subgroups. However, even within these subgroups,
loss of 17p and/or gain of 17q remain independent prog-
nostic factors for SHH, Group 3 and 4. Other factors, which
are clearly prognostic for the entire medulloblastoma
cohort, such as histology or metastasis, are barely prog-
nostic in speciﬁc subgroups and most of them do not hold
up in the multivariate analysis. Only for the SHH subgroup
does histology remain an independent prognostic factor,
and we have identiﬁed gain of 3q as a novel independent
prognostic factor for this subgroup. MYC and MYCN
ampliﬁcations also predict an unfavourable outcome in the
entire cohort (Fig. 4a), in line with previous publications
[3, 11, 17, 22]. However, MYC ampliﬁcation, most frequent
in Group 3 medulloblastomas, is not prognostic within this
subgroup (Fig. 4c). In contrast, MYCN ampliﬁcation,
mostly occurring in SHH or Group 4 medulloblastomas, is
still prognostic in both of these subgroups (Fig. 4b, d), but
did not hold up in the multivariate analyses (Table 1). Only
after correcting for age (excluding infants) MYCN ampli-
ﬁcation remains prognostic within the SHH subgroups
(Table S3). Therefore, medulloblastoma subgrouping is by
far the best factor in terms of prognostication identiﬁed to
date, but there is now a need for identifying better prog-
nostic markers within each of the subgroups. A good
example of such a subgroup-speciﬁc biomarker is the
recently identiﬁed FSTL5 protein [19]. Immunopositivity
of FSTL5 identiﬁed a large group of patients at high risk
across all medulloblastomas, but more importantly, also
within Group 3 and 4 patients.
One drawback in the survival analyses performed in this
meta-analysis is the fact that the patients contained in each
of the different GEP cohorts come from different studies,
and have been treated in multiple centers according to
different protocols. This is also demonstrated by the overall
survival of the four subgroups in the GEP cohort in com-
parison with that in the TMA cohort. All tumors in the
TMA cohort come from patients treated in a single institute
according to standardized therapeutic protocols of the
German HIT study group. Interestingly, in this TMA
cohort, patients with SHH medulloblastomas had a much
better outcome compared to the SHH medulloblastomas in
the combined GEP cohort, whereas especially patients with
Group 3 medulloblastomas had a much worse prognosis.
Furthermore, WNT medulloblastomas, reported in several
studies as having a very good outcome [2–4, 15, 17], which
is conﬁrmed in the meta-analyses of the GEP cohorts, do
not have such a good outcome in adults of the TMA cohort.
One of the reasons explaining these differences in overall
survival for the different subgroups between the GEP and
TMA cohorts could be that in general medulloblastoma
patients represented on the TMA cohort received less
intensive therapies compared to most other patients present
in the GEP cohorts. As illustrated in another paper in this
issue [10], even MYCN ampliﬁed cases in the SHH sub-
group have a better outcome when receiving less intensive
therapies. These data suggest that most, if not all SHH
medulloblastoma patients may beneﬁt from a less intensive
protocol, but other subgroups, and in particular Group 3
tumors, may not. Prospective studies targeting speciﬁc
subgroups should aim to resolve this question. Future
clinical trials will require reliable and reproducible meth-
ods to subgroup clinical medulloblastoma samples in a fast
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123way. For this, the recently developed NanoString assay can
be used, which predicts the tumor speciﬁc subgroup with
high accuracy, based on the expression level of 22 sub-
group-speciﬁc signature genes [16]. Alternatively, a panel
of immunohistochemistry-based markers can be assessed,
as demonstrated in previous publications [3, 15, 19]. As
yet, the most reliable method to attribute patients to the
four subgroups has still to be decided, but efforts are
ongoing to address this question.
In summary, we consistently ﬁnd four core molecular
subgroups of medulloblastoma across all published datasets
which are as distinct as different tumor entities and,
therefore, should be regarded as such. Thus, future studies
of medulloblastoma should accommodate this new clini-
cally useful knowledge for optimizing trial design and
treatment protocols.
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